Ai Biosciences, Inc.
College Station, TX
- UEI
- J4S6VXC9CK77
- CAGE
- 6PZP9
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 1902 Pinon Dr Ste C, College Station, TX 77845, USA
- Website
- aibiosciences.com
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $225,000 |
| FY2025 | $1,356,490 |
| FY2024 | $166,499 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | National Aeronautics and Space Administration | $225,000 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Ai Biosciences, Inc., a minority-owned, small disadvantaged business headquartered in College Station, Texas, develops point-of-care diagnostic devices and specialized sampling technologies for federal health, space, and research agencies, competing exclusively under total small business set-asides as a prime contractor. The company is Asian-Pacific American owned and self-certified as small disadvantaged, with all recent work structured as SBIR Phase I and Phase II contracts and federal research grants.
Ai Biosciences' capability portfolio centers on rapid molecular diagnostics and microgravity-compatible sampling devices for infectious disease detection and environmental monitoring. Representative work includes a $300 thousand National Institute of Allergy and Infectious Diseases contract awarded September 2025 for development of a rapid RT-LAMP assay for self-monitoring of acute or rebound HIV-1 infection using finger-prick whole blood samples; an $900 thousand SBIR Phase II contract with the Shared Services Center awarded August 2025 for a self-contained dual-mode sample preparation module using non-hazardous reagents; and a $225 thousand Shared Services Center contract awarded September 2026 for development of a hydrogel-based bioaerosol collection cartridge for in-space environmental monitoring. Earlier work includes NASA SBIR Phase I awards for a microgravity-compatible handheld squeegee-aspirator surface sampler and a microgravity-compatible liquid-free surface sampling pen, alongside National Cancer Institute SBIR funding for a rapid isothermal amplification chip for HPV detection in low-resource settings.
Customer concentration is sharp: the Shared Services Center (acting as contracting office for NASA and other civilian agencies) accounts for eight awards worth $2 million in combined potential value, and the National Institute of Allergy and Infectious Diseases represents six awards worth $1.2 million. Together these two customers account for 91% of awards across a seven-agency footprint that includes the National Cancer Institute, CDC, and the broader National Institutes of Health. By potential value, the ranking holds — Shared Services Center and NIAID anchor the portfolio, with NCI and CDC representing smaller ticket work. Awards cluster under SBIR Phase I and Phase II research structures rather than production or delivery-order vehicles; the source lists no parent IDIQs, GWACs, or standing BPAs.
Recent activity has been episodic rather than sustained — three awards in 2021, four in 2022, one in 2024, three in 2025, and one in 2026 — with no indication of steady-state prime contracting volume. Three awards with combined potential value of $1.4 million face ultimate completion inside the next twenty-four months and therefore carry recompete exposure. The vendor has no subcontractor footprint in the source data and does not appear to sub to larger primes. Federal grant work includes an NIH SBIR Phase I grant from NIAID (July 2022 through June 2024) for development of a low-cost P24 antigen test for early HIV detection and an Office of the Director grant (September 2022 through September 2023) for a rapid point-of-care molecular test for SARS-CoV-2 and influenza A/B.
Quick answers
Is Ai Biosciences, Inc. registered in SAM.gov?
Yes. Ai Biosciences, Inc.'s SAM.gov registration is active through May 22, 2027.
How much has Ai Biosciences, Inc. received in federal contracts?
Federal contracts obligated $1,356,490 to Ai Biosciences, Inc. in fiscal year 2025 and $1,747,989 in fiscal years 2023 through 2027.
How does Ai Biosciences, Inc. rank among federal contractors?
Ai Biosciences, Inc. ranked #76 in NAICS 541713 and #83 in PSC AJ14 in FY2025.
What is Ai Biosciences, Inc.'s most recent federal award?
Ai Biosciences, Inc.'s most recent federal contract award is Sbir phase i hydrogel-based bioaerosol collection cartridge for in-space environmental monitoring (80NSSC26C0194), from Shared Services Center, on September 30, 2026.
On GovTribe
See Ai Biosciences, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors